No detectable analgesic effects in the formalin test even with one million bovine adrenal chromaffin cells

Amit G. Gulwadi, Michael R. Hoane, Joel A. Saydoff, Beata R. Frydel, Mark D. Lindner

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The present experiments were conducted to identify analgesic agents for transfection into immortalized adrenal chromaffin cell lines to maximize their analgesic potential. Analgesic agents known to be produced by adrenal chromaffin cells were infused intrathecally at a low dose (0.2μg) which might conceivably be attained by adrenal chromaffin cell transplants. Numerous agents, administered individually and in two-factor combinations, produced significant analgesic effects in the formalin test. Before assessing the potential additive or synergistic effects of these analgesic agents with adrenal chromaffin cells, studies were conducted to demonstrate analgesic effects with adrenal chromaffin cells alone. Analgesic effects were previously reported in the literature with 80-100k intrathecal bovine adrenal chromaffin (BAC) cells; but in the present study 500k purified BAC cells failed to produce detectable analgesic effects. One million purified BAC cells also failed to produce analgesic effects in the formalin test. In a final study, even nicotine-stimulated release from one million purified BAC cells failed to produce analgesic effects in the formalin test. The fact that even one million nicotine-stimulated BAC cells failed to demonstrate therapeutic potential in these blinded experiments under conditions which were clearly sensitive to the analgesic agents produced by BAC cells, raises serious questions about the clinical utility of this experimental treatment.

Original languageEnglish (US)
Pages (from-to)263-271
Number of pages9
JournalPain
Volume99
Issue number1-2
DOIs
StatePublished - Sep 1 2002

Fingerprint

Chromaffin Cells
Pain Measurement
Analgesics
Nicotine
Transfection

Keywords

  • Analgesic agents
  • Bovine adrenal chromaffin cells
  • Nicotine stimulation

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

No detectable analgesic effects in the formalin test even with one million bovine adrenal chromaffin cells. / Gulwadi, Amit G.; Hoane, Michael R.; Saydoff, Joel A.; Frydel, Beata R.; Lindner, Mark D.

In: Pain, Vol. 99, No. 1-2, 01.09.2002, p. 263-271.

Research output: Contribution to journalArticle

Gulwadi, Amit G. ; Hoane, Michael R. ; Saydoff, Joel A. ; Frydel, Beata R. ; Lindner, Mark D. / No detectable analgesic effects in the formalin test even with one million bovine adrenal chromaffin cells. In: Pain. 2002 ; Vol. 99, No. 1-2. pp. 263-271.
@article{e088a6294d9d4f1e87dbfa98b511add5,
title = "No detectable analgesic effects in the formalin test even with one million bovine adrenal chromaffin cells",
abstract = "The present experiments were conducted to identify analgesic agents for transfection into immortalized adrenal chromaffin cell lines to maximize their analgesic potential. Analgesic agents known to be produced by adrenal chromaffin cells were infused intrathecally at a low dose (0.2μg) which might conceivably be attained by adrenal chromaffin cell transplants. Numerous agents, administered individually and in two-factor combinations, produced significant analgesic effects in the formalin test. Before assessing the potential additive or synergistic effects of these analgesic agents with adrenal chromaffin cells, studies were conducted to demonstrate analgesic effects with adrenal chromaffin cells alone. Analgesic effects were previously reported in the literature with 80-100k intrathecal bovine adrenal chromaffin (BAC) cells; but in the present study 500k purified BAC cells failed to produce detectable analgesic effects. One million purified BAC cells also failed to produce analgesic effects in the formalin test. In a final study, even nicotine-stimulated release from one million purified BAC cells failed to produce analgesic effects in the formalin test. The fact that even one million nicotine-stimulated BAC cells failed to demonstrate therapeutic potential in these blinded experiments under conditions which were clearly sensitive to the analgesic agents produced by BAC cells, raises serious questions about the clinical utility of this experimental treatment.",
keywords = "Analgesic agents, Bovine adrenal chromaffin cells, Nicotine stimulation",
author = "Gulwadi, {Amit G.} and Hoane, {Michael R.} and Saydoff, {Joel A.} and Frydel, {Beata R.} and Lindner, {Mark D.}",
year = "2002",
month = "9",
day = "1",
doi = "10.1016/S0304-3959(02)00120-3",
language = "English (US)",
volume = "99",
pages = "263--271",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - No detectable analgesic effects in the formalin test even with one million bovine adrenal chromaffin cells

AU - Gulwadi, Amit G.

AU - Hoane, Michael R.

AU - Saydoff, Joel A.

AU - Frydel, Beata R.

AU - Lindner, Mark D.

PY - 2002/9/1

Y1 - 2002/9/1

N2 - The present experiments were conducted to identify analgesic agents for transfection into immortalized adrenal chromaffin cell lines to maximize their analgesic potential. Analgesic agents known to be produced by adrenal chromaffin cells were infused intrathecally at a low dose (0.2μg) which might conceivably be attained by adrenal chromaffin cell transplants. Numerous agents, administered individually and in two-factor combinations, produced significant analgesic effects in the formalin test. Before assessing the potential additive or synergistic effects of these analgesic agents with adrenal chromaffin cells, studies were conducted to demonstrate analgesic effects with adrenal chromaffin cells alone. Analgesic effects were previously reported in the literature with 80-100k intrathecal bovine adrenal chromaffin (BAC) cells; but in the present study 500k purified BAC cells failed to produce detectable analgesic effects. One million purified BAC cells also failed to produce analgesic effects in the formalin test. In a final study, even nicotine-stimulated release from one million purified BAC cells failed to produce analgesic effects in the formalin test. The fact that even one million nicotine-stimulated BAC cells failed to demonstrate therapeutic potential in these blinded experiments under conditions which were clearly sensitive to the analgesic agents produced by BAC cells, raises serious questions about the clinical utility of this experimental treatment.

AB - The present experiments were conducted to identify analgesic agents for transfection into immortalized adrenal chromaffin cell lines to maximize their analgesic potential. Analgesic agents known to be produced by adrenal chromaffin cells were infused intrathecally at a low dose (0.2μg) which might conceivably be attained by adrenal chromaffin cell transplants. Numerous agents, administered individually and in two-factor combinations, produced significant analgesic effects in the formalin test. Before assessing the potential additive or synergistic effects of these analgesic agents with adrenal chromaffin cells, studies were conducted to demonstrate analgesic effects with adrenal chromaffin cells alone. Analgesic effects were previously reported in the literature with 80-100k intrathecal bovine adrenal chromaffin (BAC) cells; but in the present study 500k purified BAC cells failed to produce detectable analgesic effects. One million purified BAC cells also failed to produce analgesic effects in the formalin test. In a final study, even nicotine-stimulated release from one million purified BAC cells failed to produce analgesic effects in the formalin test. The fact that even one million nicotine-stimulated BAC cells failed to demonstrate therapeutic potential in these blinded experiments under conditions which were clearly sensitive to the analgesic agents produced by BAC cells, raises serious questions about the clinical utility of this experimental treatment.

KW - Analgesic agents

KW - Bovine adrenal chromaffin cells

KW - Nicotine stimulation

UR - http://www.scopus.com/inward/record.url?scp=0036711242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036711242&partnerID=8YFLogxK

U2 - 10.1016/S0304-3959(02)00120-3

DO - 10.1016/S0304-3959(02)00120-3

M3 - Article

VL - 99

SP - 263

EP - 271

JO - Pain

JF - Pain

SN - 0304-3959

IS - 1-2

ER -